AnthraquinonePhase 3 trialInvestigational
Vosaroxin
How it works
Interferes with DNA replication and repair, leading to cell death in cancer cells.
Cancer types
Leukemia— Acute myeloid leukemia (AML)
Efficacy
In clinical trials, vosaroxin achieved an overall response rate of around 20% in patients with relapsed or refractory AML.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.